Exit

Fund manager Neil Woodford has sold his entire stake in Oxford Sciences Innovation, worth close to $70m, as his funds have come under increasing pressure.

Personalis has filed to list on the Nasdaq Global Market through an offering that would come eight years after the genome sequencing platform was spun out of Stanford University.

Karolinska Development-backed regenerative implant producer OssDsign has booked $15.8m after selling out the original issue for its forthcoming listing, and is now looking to generate up to $2.4m from the overallotment.

Cambridge Innovation Capital has celebrated an exit as Bicycle Therapeutics successfully lists in the US.

After a year of countless exits in the ecosystem, many among the most significant yet – so much so that five nominees were not enough to recognise them all – the Award for Exit of the Year was one of the most difficult to determine.

The board at Flinders University-founded medical avatar software platform Clevertar has agreed to pump in funding to clear the spinout's outstanding liabilities to creditors including the university.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.